Lilliputian Discovers $25M, Biovex Bags $40M, Clinical Data Cedes Cogenics to Beckman Coulter for $17M, & More Boston-Area Deals News

4/6/09

(Page 2 of 2)

Genzyme will make annual payments from revenue to Bayer. The Cambridge firm will also shell out $75 million to $100 million for a Seattle-area factory to produce one of the drugs.

—Nano-Terra, a nanotechnology research and development firm based in Cambridge, MA, announced it will develop new surface materials for water treatment in partnership with Minneapolis-based Pentair (NYSE:PNR). Financial terms of the deal were not disclosed.

—Newton, MA-based Clinical Data (NASDAQ:CLDA) cut a deal to sell its outsourced genomics research business, Cogenics, for about $17 million to Orange County, CA-based life sciences company Beckman Coulter (NYSE:BEC).

Lilliputian Systems of Wilmington, MA, reportedly raised $25 million to support the development of tiny fuel cells for mobile phones and laptops. The round, which brings Lilliputian’s total raised to about $90 million, included new investors Stata Venture Partners of Needham, MA, and Altira Group of Denver, and repeat investors Atlas Venture, Fairhaven Capital, RockPort Capital Partners, and Kleiner Perkins Caufield and Byers.

—Cadec Global, a Manchester, NH-based maker of GPS tracking, logging, and safety equipment for truck fleets, hauled in $4 million in new financing from existing investor Thule Investments of Reykjavik, Iceland.

—Sepaton, a maker of various products for enterprise data protection based in Marlborough, MA, raised $15.5 million in a Series F round led by new investor Focus Ventures of Palo Alto, CA. The round was joined by Jerusalem Venture Partners, Menlo Ventures, Valhalla Partners, and HarbourVest Partners, all return investors.

—Wireless chipmaker M/A-COM Technology Solutions of Lowell, MA, was acquired by John Ocampo, the owner of California private equity fund GaAs Labs, for $30 million in cash and $30 million in senior loan notes. Another $30 million is on the table, depending on future M/A-COM revenues.

—Waltham, MA-based skin-treatment developer Magen BioSciences was acquired by Wilmington, N.C.-based contract research firm PPD (NASDAQ:PPDI) for just $14.5 million. In 2006, Magen raised $15.4 million in a Series A round of financing led by Highland Capital Partners and joined by Flybridge Venture Partners (formerly IDG Ventures) and Lux Capital.

Single Page Currently on Page: 1 2 previous page

By posting a comment, you agree to our terms and conditions.